At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MTVA MetaVia Inc
Trading 08-24 13:06:08 EDT
1.51
+0.05
+3.37%
High1.53Low1.44Vol32.14K
Open1.46D1 Closing1.46Amplitude6.16%
Mkt Cap9.94MTradable Cap7.25MTotal Shares6.59M
T/O48.35KT/O Rate0.67%Tradable Shares4.81M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Wall Street Analysts Are Bullish on Top Healthcare Picks
TIPRANKS  ·  08-19
Wall Street Analysts Are Bullish on Top Healthcare Picks
MetaVia Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-07
MetaVia Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
MetaVia Q2 EPS $(0.90) Misses $(0.82) Estimate
Benzinga Earnings  ·  08-07
MetaVia Q2 EPS $(0.90) Misses $(0.82) Estimate
MetaVia Q2 FY26 Net Loss Widens to $5.3 Million
Reuters  ·  08-07
MetaVia Q2 FY26 Net Loss Widens to $5.3 Million
MetaVia Inc Expected to Post a Loss of 82 Cents a Share - Earnings Preview
Reuters  ·  08-03
MetaVia Inc Expected to Post a Loss of 82 Cents a Share - Earnings Preview
Analyst Reaffirms Buy on MTVA as DA-1726 Data De-Risk Obesity and MASH Opportunity; Price Target Maintained at $20
TIPRANKS  ·  07-10
Analyst Reaffirms Buy on MTVA as DA-1726 Data De-Risk Obesity and MASH Opportunity; Price Target Maintained at $20
Metavia Price Target Maintained with a $20.00/share by HC Wainwright & Co.
Dow Jones  ·  07-10
Metavia Price Target Maintained with a $20.00/share by HC Wainwright & Co.
Metavia Says All Active Patients Reach Highest Target Doses in Da-1726 Obesity Phase 1 Part 3 Study
Reuters  ·  07-09
Metavia Says All Active Patients Reach Highest Target Doses in Da-1726 Obesity Phase 1 Part 3 Study
Metavia - All Patients Reach Highest Target Doses of 48 Mg and 64 Mg in Phase 1 Part 3
THOMSON REUTERS  ·  07-09
Metavia - All Patients Reach Highest Target Doses of 48 Mg and 64 Mg in Phase 1 Part 3
Metavia - Topline Data from Phase 1 Part 3 Expected in Q4 2026
THOMSON REUTERS  ·  07-09
Metavia - Topline Data from Phase 1 Part 3 Expected in Q4 2026
Metavia Announces Completion of Dose Titration in Phase 1 Part 3 Study of Da-1726 for the Treatment of Obesity
THOMSON REUTERS  ·  07-09
Metavia Announces Completion of Dose Titration in Phase 1 Part 3 Study of Da-1726 for the Treatment of Obesity
MetaVia CEO to join Life Sciences Virtual Investor Forum fireside chat on obesity, metabolic therapies
Reuters  ·  06-17
MetaVia CEO to join Life Sciences Virtual Investor Forum fireside chat on obesity, metabolic therapies
Analysts Offer Insights on Healthcare Companies: MetaVia (MTVA) and Adlai Nortye Ltd. Sponsored ADR (ANL)
TIPRANKS  ·  06-09
Analysts Offer Insights on Healthcare Companies: MetaVia (MTVA) and Adlai Nortye Ltd. Sponsored ADR (ANL)
BRIEF-Biostem Technologies Announces Appointment Of Three New Members To Its Board Of Directors
Reuters  ·  06-09
BRIEF-Biostem Technologies Announces Appointment Of Three New Members To Its Board Of Directors
Biostem Technologies Announces Appointment of Three New Members to Its Board of Directors
THOMSON REUTERS  ·  06-09
Biostem Technologies Announces Appointment of Three New Members to Its Board of Directors
Metavia - Stockholders Approve Reverse Stock Split at Ratio Between 1-for-5 and 1-for-22 - SEC Filing
THOMSON REUTERS  ·  06-09
Metavia - Stockholders Approve Reverse Stock Split at Ratio Between 1-for-5 and 1-for-22 - SEC Filing
MetaVia shareholders approved 200,000-share increase to equity incentive plan at annual meeting
Reuters  ·  06-09
MetaVia shareholders approved 200,000-share increase to equity incentive plan at annual meeting
MetaVia presents data at ADA supporting DA-1726, vanoglipel
TIPRANKS  ·  06-08
MetaVia presents data at ADA supporting DA-1726, vanoglipel
MetaVia says Phase 1 trial shows DA-1726 cuts mean body weight up to 9.1% by Day 54
Reuters  ·  06-08
MetaVia says Phase 1 trial shows DA-1726 cuts mean body weight up to 9.1% by Day 54
MetaVia to present at Emerging Growth Conference on obesity, metabolic therapy pipeline
Reuters  ·  06-04
MetaVia to present at Emerging Growth Conference on obesity, metabolic therapy pipeline

Introduction

Company Name.
MetaVia Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Issue price:
--